The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients

HR Kim, MS Kang, II Na, SH Yang, YH Choi… - Journal of cancer …, 2010 - Springer
Purpose Pemetrexed is a recognized active agent for the second-line treatment for
advanced non-small cell lung cancer (NSCLC). This study was undertaken to evaluate the …
被引用次数：8 相关文章

The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients.

HR Kim, MS Kang, SH Yang, YH Choi… - Journal of Cancer …, 2010 - search.ebscohost.com
Pemetrexed is a recognized active agent for the second-line treatment for advanced non-
small cell lung cancer (NSCLC). This study was undertaken to evaluate the clinical benefits …

The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients

HR Kim, MS Kang, SH Yang, YH Choi, HJ Kang… - Journal of Cancer …, 2010 - infona.pl
Purpose Pemetrexed is a recognized active agent for the second-line treatment for
advanced non-small cell lung cancer (NSCLC). This study was undertaken to evaluate the …

The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients.

HR Kim, MS Kang, II Na, SH Yang, YH Choi… - Journal of Cancer …, 2009 - europepmc.org
Purpose Pemetrexed is a recognized active agent for the second-line treatment for
advanced non-small cell lung cancer (NSCLC). This study was undertaken to evaluate the …

The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients

H Kim, MS Kang, SH Yang, YH Choi… - Journal of Cancer …, 2010 - search.proquest.com
Pemetrexed is a recognized active agent for the second-line treatment for advanced non-
small cell lung cancer (NSCLC). This study was undertaken to evaluate the clinical benefits …

The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients

HR Kim, MS Kang, SH Yang… - Journal of cancer …, 2010 - pubmed.ncbi.nlm.nih.gov
Purpose Pemetrexed is a recognized active agent for the second-line treatment for
advanced non-small cell lung cancer (NSCLC). This study was undertaken to evaluate the …

[引用][C] The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients

HR KIM, MINSOO KANG, NA IM IL… - Journal of cancer …, 2010 - pascal-francis.inist.fr
The similar survival benefits of stable disease and partial response to pemetrexed in
previously treated non-small cell carcinoma patients CNRS Inist Pascal-Francis CNRS …

The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients

HR Kim, MS Kang, SH Yang, YH Choi, HJ Kang… - Journal of Cancer …, 2010 - infona.pl
Purpose Pemetrexed is a recognized active agent for the second-line treatment for
advanced non-small cell lung cancer (NSCLC). This study was undertaken to evaluate the …

[引用][C] The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients

HR Kim, MS Kang, II Na, SH Yang, YH Choi… - Journal of Cancer …, 2010 - Springer

[引用][C] The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients

HR KIM, MINSOO KANG, NA IM IL, SH YANG… - Journal of cancer …, 2010 - Springer